Buprenorphine is a Schedule III opioid analgesic with unique pharmacodynamic and
pharmacokinetic properties that may be preferable to those of Schedule II full μ-opioid …

This paper is the 28th consecutive installment of the annual review of research concerning
the endogenous opioid system, now spanning over a quarter-century of research. It …

Description: In May 2022, leadership within the US Department of Veterans Affairs (VA) and
US Department of Defense (DoD) approved a joint clinical practice guideline for the use of …

Buprenorphine was not used widely in clinical practice over many years, mainly due to
analgesic potency and clinical safety concerns based on misinterpreted animal data …

Background: Pain is one of the most common symptoms in cancer patients. The Japanese
Society for Palliative Medicine (JSPM) first published its clinical guidelines for the …

Pain ranges in prevalence from 14–100% among cancer patients and occurs in 50–70% of
those in active treatment. Cancer pain may result from direct invasion of tumor into nerves …

Background Many patients with cancer experience moderate to severe pain that requires
treatment with strong analgesics. Buprenorphine, fentanyl and morphine are examples of …

BACKGROUND: In all recommended guidelines put forth for the treatment of cancer pain,
opioids continue to be an important part of a physician's armamentarium. Though opioids …

Background: To assess the adverse effects of transdermal opiates treating moderate-severe
cancer pain in comparison with slow release oral morphine. Methods: A systematic review of …

Chronic pain in the elderly is a significant problem. Pharmacokinetic and metabolic changes
associated with increased age makes the elderly vulnerable to side effects and overdosing …